Other equities research analysts have also issued reports about the company. LADENBURG THALM/SH SH lowered Renovacor from a buy rating to a neutral rating in a research report on Tuesday. Robert W. Baird initiated coverage on shares of Renovacor in a report on Monday, September 12th. They issued an outperform rating on the stock. Finally, Lifesci Capital restated an outperform rating on shares of Renovacor in a research report on Thursday, June 16th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of Moderate Buy and an average price target of $21.00.
Renovacor Stock Performance
Shares of RCOR opened at $2.18 on Tuesday. Renovacor has a 52-week low of $1.34 and a 52-week high of $10.47. The stock’s 50-day simple moving average is $1.86 and its 200 day simple moving average is $2.65. The stock has a market capitalization of $37.64 million, a price-to-earnings ratio of -2.99 and a beta of 0.09.
Institutional Inflows and Outflows
Renovacor, Inc, a biotechnology company, focuses on delivering various precision therapies to enhance the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases. It primarily focuses on the treatment of BCL2-associated athanogene 3 (BAG3) mutation-associated dilated cardiomyopathy (DCM).
- Get a free copy of the StockNews.com research report on Renovacor (RCOR)
- 3 Airline Stocks Stuck in a Holding Pattern
- Roku Stock is Down but Not Out
- If You’re Hungry for Value, Take a Bite on Ruth’s Hospitality Grp
- Is Ford Rolling To A Rebound After Its Q3 Warning
- Has AMD stock stock fallen too far?
Receive News & Ratings for Renovacor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Renovacor and related companies with MarketBeat.com's FREE daily email newsletter.